Results · Apr-Jun 2026
Alivus Life Sciences Q1 FY27 results
Sales grew 6% to ₹640 crore from ₹602 crore in Apr-Jun 2025.
Operating profit grew 23% to ₹212 crore, an operating margin of 33.1% (up 4.4 points from a year ago).
Net profit grew 32% to ₹160 crore from ₹122 crore in Apr-Jun 2025.
Against Jan-Mar 2026: sales −7%, net profit −2%.
Apr-Jun 2026 vs a year ago
| ₹ crore | Apr-Jun 2026 | Apr-Jun 2025 | Change |
|---|---|---|---|
| Sales | 640.4 | 601.8 | +6% |
| Operating profit (EBITDA) | 211.7 | 172.3 | +23% |
| Operating margin | 33.1% | 28.6% | +4.4 pts |
| Net profit | 160.1 | 121.5 | +32% |
Standalone figures. Margins & ratios change in percentage points (pts).
The last 7 quarters
From the company's results filed on BSE (Standalone). Business numbers only. Education & analysis, not investment advice or a recommendation.